Two small-cap biotech stocks offer high risk but significant upside for patient investors as they advance early-stage diagnostic and antiviral programs
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nurix Therapeutics (NRIX – Research Report) and Mainz Biomed B.V. (MYNZ – Research Report) with bullish...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Mainz Biomed...
Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%.
Mainz Biomed partners with Quest Diagnostics to commercialize a colorectal cancer screening test, enhancing early detection efforts.Quiver AI SummaryMainz Biomed N.V. has announced a partnership with Quest...
Mainz Biomed closed a follow-on offering, raising approximately $8 million through the sale of 1,367,521 units.Quiver AI SummaryMainz Biomed N.V. has successfully completed a follow-on offering of 1,367,521...
Mainz Biomed announces $8 million follow-on offering of 1,367,521 units, including shares and warrants, priced at $5.85 each.Quiver AI SummaryMainz Biomed N.V. has announced a follow-on offering of 1,367,521...
Mainz Biomed announces a 1-for-40 reverse stock split to meet Nasdaq listing standards, effective December 3, 2024.Quiver AI SummaryMainz Biomed N.V. has announced a 1-for-40 reverse stock split, effective...
Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today
Maintaining a healthy weight is important for general health, but growing evidence reveals obesity’s role in the development of chronic illnesses and even deadly cancers. Obesity is one of the most frequent...